Revolution Medicines said its orally dosed RAS inhibitor daraxonrasib significantly extended survival versus chemotherapy in a Phase 3 trial in metastatic pancreatic ductal adenocarcinoma, strengthening the clinical case for targeting RAS(ON). The company reported a 60% reduction in the risk of death for patients included in the study and said median overall survival doubled. Multiple reports in the feed indicate the company is preparing to submit the Phase 3 data to the FDA for approval, potentially via a fast-track pathway. If supported by regulators, it would represent a major shift for advanced PDAC where treatment options remain limited. Separately, STAT coverage highlighted the patient-level impact of the trial as well, underscoring how daraxonrasib is being positioned for real-world adoption if the US review moves quickly.